Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.3252W HIGH $5.08
Volume
231.40 K
Value Traded
705.79 K
Short % Float
0.6%
-7.45%Week
-22.62%1 Month
-46.12%3 Month
-40.4%6 Month
-60.55%5 Year
+450.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
99.41 M
EPS (TTM)
-0.20
P/E Ratio
-
Ent. Value
109.30 M
Total Shares
42.11 M
Float Shares
36.41 M
Insiders
13.56%
Institutions
50.57%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
APYX Catalyst Timeline
Dated clinical, regulatory and corporate events for Apyx Medical Corporation
Past FDA Catalysts and PDUFA Decisions
How APYX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Apyx Medical Corporation is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every APYX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Renuvion | skin quality improvement | 2026-09-29 | 30% increase in elastin fiber density; 34% reduction in inflammation; 100% of participants demonstrated improvement in aesthetic scores; 100% of participants reported improvement and satisfactionRead More | Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin QualityRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Waldman LawrenceDirector | Option | 12,000 17,338 held | $1.88 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in APYX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 321.00 K | 150.00 K |
APYX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How APYX ranks across every disease it competes in
Competitive Position is a premium feature
See how APYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAPYX News
APYXApyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
Apyx Medical Corporation announced positive results from a clinical study of Renuvion, showing significant improvements in skin quality. The study indicated a 30% increase in elastin density and a 34% reduction in inflammation in treated tissues. All participants reported satisfaction with their treatment outcomes and visible improvements in skin elasticity and radiance. The findings support Renuvion's efficacy in enhancing surgical aesthetics.
Read more →APYXApyx Medical Corporation Reports Second Quarter 2026 Financial Results
Apyx Medical Corporation reported second quarter 2026 financial results, showing total revenue of $13.9 million, a 22% increase from the previous year. The Surgical Aesthetics segment experienced significant growth, driven by the AYON platform. The company reaffirmed its revenue guidance for the fiscal year 2026, despite a net loss of $3.2 million.
Read more →APYXApyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
Apyx Medical Corporation announced its participation in the Canaccord Genuity 46th Annual Growth Conference scheduled for August 11, 2026. CEO Charlie Goodwin and CFO Matt Hill will engage in a fireside chat and hold one-on-one meetings with investors. The event will be accessible via live webcast, promoting transparency and investor engagement.
Read more →APYXApyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Apyx Medical Corporation will announce its financial results for Q2 2026 on August 6, 2026, after market close. A conference call will follow at 4:30 p.m. ET for discussion and Q&A. The company specializes in surgical aesthetics, with products like Renuvion and AYON Body Contouring System, supported by extensive clinical documentation.
Read more →APYXBody by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
Apyx Medical Corporation will showcase its Body by Apyx at Miami Swim Week, highlighting real patient transformations. The event will feature the AYON Body Contouring System, which integrates various body contouring technologies. This initiative aims to reshape beauty standards and meet the growing demand for body contouring procedures, emphasizing authenticity and patient journeys.
Read more →APYX▲ +12.1%on this newsshared move
New Study Shows Significant Improvement in Cellulite and Skin Laxity With Advanced Minimally Invasive Treatment Utilizing Avéli™ and Renuvion®
Apyx Medical Corporation announced promising results from a clinical study published in Aesthetic Surgery Journal Open Forum. The study evaluated a combination treatment using Avéli for targeted subcision and Renuvion for skin laxity, showing significant improvements in cellulite and skin quality. Results indicated up to 81.8% of patients experienced visible reductions in cellulite appearance over 180 days.
Read more →APYX▲ +13.5%on this news
Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
Apyx Medical Corporation announced a new retrospective study published in 'Plastic and Reconstructive Surgery - Global Open', evaluating the benefits of Renuvion when combined with liposuction. The study found that patients using Renuvion reported higher satisfaction with their abdominal appearance and experienced lower rates of abdominoplasty and surgical revisions, while complication rates remained comparable to traditional methods.
Read more →APYX▲ +6.8%on this news· ran to +19% by day 3shared move
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Apyx Medical Corporation has received expanded FDA 510(k) clearance for its AYON Body Contouring System, now including power liposuction capabilities. This advancement aims to improve surgical efficiency and reduce operating room time. The company plans a limited commercial launch to enhance training and customer experience before broader adoption.
Read more →APYX▲ +21.9%on this news· ran to +40% by day 3shared move
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
Apyx Medical Corporation reported a total revenue of $12.5 million for Q1 2026, marking a 36% increase in its Surgical Aesthetics segment. The company raised its revenue guidance for the full year to between $59.0 million and $60.0 million. Despite a net loss of $2.1 million, the company remains optimistic about its growth, particularly in international markets like South Korea.
Read more →APYXApyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
Apyx Medical Corporation will announce its financial results for the first quarter of fiscal year 2026 on May 7, 2026. The announcement will be followed by a conference call at 8:00 a.m. ET, where management will discuss the results and answer questions. The company specializes in surgical aesthetics, offering innovative products like Renuvion and the AYON Body Contouring System.
Read more →APYXRenuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Apyx Medical Corporation's Renuvion has won the NewBeauty Award for "Best Minimally Invasive Skin Tightener" for the second consecutive year. This recognition highlights the device's effectiveness in body contouring and its role in enhancing patient confidence. Renuvion is noted for being the only FDA-cleared technology for use after liposuction, further solidifying its position in the market.
Read more →APYXApyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Apyx Medical Corporation reported strong financial results for Q4 and the full year of 2025, with total revenue reaching a record $19.2 million. The company attributed its success to substantial growth in its Surgical Aesthetics segment, particularly from the AYON Body Contouring System. However, while the Surgical Aesthetics segment saw nearly 50% growth in U.S. sales, net losses persisted at $1.3 million for the quarter. Looking ahead, Apyx expects total revenue for FY2026 to fall between $57.5 million and $58.5 million.
Read more →APYXApyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026
Apyx Medical Corporation announced it will release its fourth quarter financial results for fiscal year 2025 on March 10, 2026. A conference call will follow at 8:00 a.m. ET, allowing stakeholders to discuss the results. The company is known for its innovative surgical aesthetics products, including Renuvion and the AYON Body Contouring System.
Read more →APYXApyx Medical Corporation to Participate in The Citizens Life Sciences Conference
Apyx Medical Corporation announced its participation in The Citizens Life Sciences Conference on March 11, 2026, in Miami, FL. CEO Charlie Goodwin and CFO Matt Hill will engage in a fireside chat and hold one-on-one meetings with investors. The event will be accessible via live webcast, with a replay available later.
Read more →APYXApyx Medical Corporation To Participate In The Citizens Life Sciences Conference
Apyx Medical Corporation announced its participation in The Citizens Life Sciences Conference on March 11, 2026, in Miami, FL. CEO Charlie Goodwin and CFO Matt Hill will engage in a fireside chat and hold one-on-one meetings with investors. The event highlights Apyx's innovative products in surgical aesthetics, including Renuvion and the AYON Body Contouring System.
Read more →APYXApyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Apyx Medical Corporation announced its participation in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference scheduled for February 10, 2026, in Snowbird, Utah. The company is known for its innovative surgical aesthetics products, including Renuvion and the AYON Body Contouring System. Investors can request meetings through their BTIG representatives.
Read more →APYXApyx Medical Corporation To Participate At The BTIG 13th Annual Medtech, Digital Health, Life Science & Diagnostic Tools Conference
Apyx Medical Corporation announced its participation in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026, in Snowbird, Utah. The company is known for its surgical aesthetics products, including Renuvion and the AYON Body Contouring System. These products are backed by over 90 clinical documents, highlighting their effectiveness.
Read more →APYX▲ +14.9%on this news
Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
Apyx Medical Corporation has announced preliminary revenue results for the fourth quarter and full year of 2025, showcasing a strong increase in total revenues. For Q4 2025, the total revenue is projected to be around $19 million, signifying a 34% year-over-year increase. The company's Surgical Aesthetics revenue also displayed a notable rise of approximately 38%. However, the OEM revenue experienced a decline of 21% year-over-year, highlighting areas of concern amidst overall growth.
Read more →APYXApyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea
Apyx Medical Corporation has announced the approval and commercial launch of its Apyx One console and single-use handpieces in South Korea, following regulatory approval from the Ministry of Food and Drug Safety. The company is set to start shipping these products in the fourth quarter of 2025. The Apyx One console features a multifunctional design aimed at enhancing cosmetic surgical procedures. With South Korea's cosmetic surgery market expected to reach $3.9 billion by 2033, Apyx plans to cater to the increasing demand for body contouring technologies.
Read more →APYX▼ -5.5%on this news
Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock
Apyx Medical Corporation has announced the pricing of its public offering of 2,762,431 shares at $3.62 per share, set to close around November 19, 2025. The company aims to use the net proceeds for working capital and general corporate purposes. This offering is part of a shelf registration statement and reflects the company's commitment to expanding its market presence. Lucid Capital Markets is acting as the sole manager for the offering, which includes an underwriter option for additional shares.
Read more →About Apyx Medical Corporation
Headquarters5115 ULMERTON ROAD, CLEARWATER, FL, 33760
Founded1978
BIOPHARMAWATCH ELITE PLUS
Trade the next APYX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime